Physician profile
Richard James
NPI 1962445478
$4,699.48
in general payments reported to CMS, 2019-2025
17 companies · $701 in 2025
The $701 reported for 2025 was more than what 81% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $152 · 2021: $477 · 2022: $626 · 2023: $815 · 2024: $594 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $705.27 | 2019-2024 | Austedo Xr |
| Abbvie INC. | $685.01 | 2021-2023 | |
| Axsome Therapeutics, INC. | $569.43 | 2023-2025 | Auvelity |
| Allergan, INC. | $568.12 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $301.36 | 2021-2025 | Qelbree |
| Jazz Pharmaceuticals INC. | $290.85 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $253.22 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.07 | 2024-2025 | Caplyta |
| Alkermes, INC. | $216.51 | 2023-2024 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $124.03 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $119.53 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $107.95 | 2022 | |
| Tms Neurohealth Centers INC. | $101.86 | 2025 | Tms Neurohealth Centers INC. |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.10 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $94.05 | 2019 | |
| Neuronetics, INC. | $93.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.